Here’s How to Avoid a COVID-19 Vaccine Mix-Up
Recognizing the potential for vaccine administration errors with look-alike vials, CDC staff shared best practices for giving the right vaccine to the right person at the right dose, during a Clinician Outreach and Communication Activity (COCA) webinar earlier this week. The most concerning possible vaccination error would be that a child might receive a higher […]
Health Workers Unlikely to Catch Monkeypox From Infected Patients
Healthcare personnel (HCP) were unlikely to be infected with monkeypox from an infected patient, according to research from the Colorado Department of Public Health and Environment. Among 313 healthcare workers exposed to 55 patients with confirmed monkeypox, none contracted the virus over 21 days of follow-up, even though many did not wear personal protective equipment […]
Young Black Twin Sisters Were Unjustly Committed To A Mental Hospital. A New Film Aims To Unravel The Truth.
The story of June and Jennifer Gibbons remains as confounding as ever — even with multiple on-screen and print iterations. The identical twins spent most of their lives mirroring each other’s every move. They only spoke to each other, not even their family, in a language they stitched together on their own (a blend between […]
Adult ADHD linked to elevated risk of cardiovascular diseases
Adults with ADHD are at greater risk of developing a range of cardiovascular diseases than those without the condition, according to a large observational study led by researchers at Karolinska Institutet and Örebro University in Sweden. The researchers say the findings, published in the journal World Psychiatry, underscore the need to monitor cardiovascular health in […]
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer
PARIS — Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients responded to frontline enfortumab vedotin (EV; Padcev) and pembrolizumab (Keytruda), including eight complete responses. An additional 17 patients had stable disease, resulting in a clinical […]
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma
PARIS — While pembrolizumab (Keytruda) has been approved as an adjuvant treatment for patients with high-risk renal cell carcinoma (RCC), three phase III studies presented at the European Society for Medical Oncology (ESMO) annual congress here failed to support the immune checkpoint inhibitor in this setting. In Part A of the CheckMate-914 trial, the median […]
Tecovirimat Safe in Monkeypox, but Efficacy Is Less Clear
Tecovirimat (Tpoxx) was well tolerated among patients with monkeypox virus infection, though its efficacy in monkeypox is currently unclear, CDC researchers said. Among over 300 patients taking tecovirimat under the FDA-regulated Expanded Access Investigational New Drug (EA-IND) protocol, 6.9% were hospitalized after symptom onset, with a median duration of hospitalization of 4 days, reported Farrell […]
Scientists redefine obesity with discovery of two major subtypes
A team led by Van Andel Institute scientists has identified two distinct types of obesity with physiological and molecular differences that may have lifelong consequences for health, disease and response to medication. The findings, published today in the journal Nature Metabolism, offer a more nuanced understanding of obesity than current definitions and may one day […]
More And More People Have ‘Lifestyle Fatigue.’ Maybe You Do, Too.
Even though we’re armed with COVID-19 vaccines and updated booster shots, the world is still largely in a different (and oft-worried) place compared with before the pandemic. This, experts say, can lead to a feeling of malaise — or “lifestyle fatigue,” in the words of Sean Grover, a psychotherapist who writes for Psychology Today. Lifestyle […]
‘Potential New Standard’ for Progressing Desmoid Tumors
PARIS — Progression-free survival (PFS) was significantly prolonged in patients with progressing desmoid tumors treated with an investigational gamma secretase inhibitor in a phase III trial. In the international DeFi study of more than 140 patients, risk for disease progression or death was reduced by 71% in the group randomized to nirogacestat, with a median […]